bluuebunny/crossref_metadata_2025_split huggingface dataset:
Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody
Authors: Burmester Gerd R. , McInnes Iain B. , Kremer Joel M. , Miranda Pedro , Vencovský Jiří , Godwood Alex , Albulescu Marius , Michaels M. Alex , Guo Xiang , Close David , Weinblatt Michael 
Published: January 2018

ObjectiveMavrilimumab, a human monoclonal antibody, targets granulocyte–macrophage colony‐stimulating factor receptor α. We undertook to determine the long‐term safety and efficacy of mavrilimumab in rheumatoid arthritis patients in 2 phase IIb studies (1071 and 1107) and in 1 open‐label extension study (ClinicalTrials.gov identifier: NCT01712399).MethodsIn study 1071, patients with an inadequate response to disease‐modifying antirheumatic drugs (DMARDs) received mavrilimumab (30, 100, or 150 mg) or placebo every other week plus methotrexate. In study 1107, patients with an inadequate response to anti–tumor necrosis factor agents and/or DMARDs received 100 mg mavrilimumab every other week or 50 mg golimumab every 4 weeks plus methotrexate. Patients entering the open‐label extension study received 100 mg mavrilimumab every other week plus methotrexate. Long‐term safety and efficacy of mavrilimumab were assessed.ResultsA total of 442 patients received mavrilimumab (14 of 245 patients from study 1071, 9 of 70 patients from study 1107, and 52 of 397 patients from the open‐label extension study discontinued mavrilimumab treatment throughout the studies). The cumulative safety exposure was 899 patient‐years; the median duration of mavrilimumab treatment was 2.5 years (range 0.1–3.3 years). The most common treatment‐emergent adverse events (AEs) were nasopharyngitis (n = 69; 7.68 per 100 patient‐years) and bronchitis (n = 51; 5.68 per 100 patient‐years). At weeks 74 and 104, 3.5% and 6.2% of patients, respectively, demonstrated reduction in forced expiratory volume in 1 second, while 2.9% and 3.4% of patients, respectively, demonstrated reduction in forced vital capacity (>20% reduction from baseline to <80% predicted). Most pulmonary changes were transient and only infrequently associated with AEs. Mavrilimumab at 100 mg every other week demonstrated sustained efficacy; at week 122, 65.0% of patients achieved a Disease Activity Score in 28 joints using the C‐reactive protein level (DAS28‐CRP) of <3.2, and 40.6% of patients achieved a DAS28‐CRP of <2.6.ConclusionLong‐term treatment with mavrilimumab maintained response and was well‐tolerated with no increased incidence of treatment‐emergent AEs. Safety data were comparable with those from both phase IIb qualifying studies.
Insights on the structure‐activity relationship of peptides derived from Sticholysin II
Authors: Lima de Oliveira Aline , Maffud Cilli Eduardo , Ros Uris , Crusca Jr Edson , Lanio María Eliana , Alvarez Carlos , Schreier Shirley , Aguiar Pertinhez Thelma , Spisni Alberto 
Published: January 2018

AbstractSticholysin II (StII) is a pore‐forming actinoporin from the sea anemone Stichodactyla helianthus. A mechanistic model of its action has been proposed: proteins bind to cell membrane, insert their N‐termini into the lipid core and assemble into homo‐tetramer pores responsible for host‐cell death. Because very likely the first 10 residues of StII N‐terminus are critical for membrane penetration, to dissect the molecular details of that functionality, we studied two synthetic peptides: StII1‐30 and StII16‐35. They show diverse haemolytic and candidacidal activity that correlate with distinct orientations in SDS micelles. NMR shows that StII1‐30 partly inserts into the micelle, while StII16‐35 lays on the micelle surface. These results justify the diverse concentration dependence of their candidacidal activity supposing a different mechanism of action and providing new hints on StII lytic activity at molecular level. Biotechnological application of these peptides, focused on the development of therapeutic immunocomplexes, may be envisaged.
Intentional longitudinal and side‐cell stent fractures: Intermediate term follow up
Authors: Agrawal Hitesh , Qureshi Athar M. , Justino Henri 
Published: January 2018

AbstractBackgroundUse of small diameter stents in young children and jailing of side branches pose significant challenges to future re‐interventions. We sought to assess the capacity to induce longitudinal fractures in undersized stents to increase vessel diameter, and side cell fractures to enlarge stenotic jailed branches.MethodsRetrospective review of patients who underwent attempted intentional stent fractures (ISF) from 01/06‐02/17.ResultsTwenty‐two patients, median age 4.4 (1.1–47.8) years, weighing 14.3 (6.9–102) kg underwent attempted ISF in 32 vessels. Initial stent implant occurred at a median age of 1.0 (0.1–34.1) years, at the following sites: pulmonary arteries (11), pulmonary veins (14), systemic veins (6), and aorta (1). Initial diameters of the stents were 3.5–12 mm. Thirteen vessels had overlapping stents. Using high‐pressure balloons, longitudinal ISF was achieved in 23 and side cell ISF in eight vessels. One longitudinal ISF attempt was unsuccessful. Three lesions were immediately re‐stented after longitudinal ISF, and three lesions treated with angioplasty (1) or stenting (2) after side cell ISF. Only one complication occurred (pseudoaneurysm in a pulmonary artery after longitudinal ISF requiring placement of a covered stent). At a median follow up of 2.0 years (2 days – 10.8 years), eight patients had 16 additional interventions for restenosis at site of ISF.ConclusionsISF can be induced safely in a variety of vascular beds using high‐pressure balloons both longitudinally or through side cells. Longitudinal ISF only rarely requires immediate placement of a new stent; however, late restenosis may occur, requiring re‐stenting.
Angiographic follow‐up of infants and children undergoing percutaneous carotid artery interventions
Authors: Ligon R. Allen , Kim Dennis W. , Vincent Robert N. , Bauser‐Heaton Holly D. , Ooi Yinn K. , Petit Christopher J. 
Published: January 2018

AbstractObjectiveThe purpose of this study was to review the outcomes following the percutaneous carotid arterial (PCA) approach in infants and children with congenital heart disease.BackgroundPCA access is becoming more commonly adopted following reports demonstrating it is a safe alternative to surgical carotid cutdown and even the femoral arterial route. However, follow‐up outcomes after PCA remain unreported.MethodsWe reviewed all cases with PCA access and follow‐up catheterizations which included carotid artery (CA) angiography between May 2012 until December 2016. We examined for evidence of CA stenosis at follow‐up angiography and assessed any other CA complications associated with vascular access.ResultsThere were 61 PCA catheterizations performed in 55 unique patients. Follow‐up CA imaging with angiography was available in 43 patients (78%, 43/55). There was no vessel stenosis nor lumen irregularity in 28 (65%) patients. In 15 cases (35%), there was a mild degree of irregularity or narrowing by angiography (median 4.1%, range 2.3%–12.5%). Nine patients underwent repeat PCA catheterizations. Seven of these had no visible vascular stenosis on follow‐up angiographic imaging, including a patient who was accessed three separate times from the CA. No statistically significant risk factors for developing mild CA stenosis were identified.ConclusionsPCA access for pediatric interventional catheterization appears to be safe with a very low rate of mild stenosis, and very few complications. Follow‐up outcomes in our series are excellent, with a CA patency rate of 100%, even after multiple procedures. Mild CA stenosis was not associated with patient size or sheath introducer caliber. While the acute results from percutaneous CA catheterization have proven safe in recent literature, longer‐term outcomes remain unreported. At our institution, the outcomes following percutaneous carotid access are associated with an excellent patency rate of 100%, even after multiple procedures on the same vessel. A low incidence of mild vessel stenosis can be appreciated on follow‐up angiography.
Three‐dimensional prototyping for procedural simulation of transcatheter mitral valve replacement in patients with mitral annular calcification
Authors: El Sabbagh Abdallah , Eleid Mackram F. , Matsumoto Jane M. , Anavekar Nandan S. , Al‐Hijji Mohammed A. , Said Sameh M. , Nkomo Vuyisile T. , Holmes David R. , Rihal Charanjit S. , Foley Thomas A. 
Published: January 2018

AbstractIntroductionThree‐dimensional (3D) prototyping is a novel technology which can be used to plan and guide complex procedures such as transcatheter mitral valve replacement (TMVR).MethodsEight patients with severe mitral annular calcification (MAC) underwent TMVR. 3D digital models with digital balloon expandable valves were created from pre‐procedure CT scans using dedicated software. Five models were printed. These models were used to assess prosthesis sizing, anchoring, expansion, paravalvular gaps, left ventricular outflow tract (LVOT) obstruction, and other potential procedure pitfalls. Results of 3D prototyping were then compared to post procedural imaging to determine how closely the achieved procedural result mirrored the 3D modeled result.Results3D prototyping simulated LVOT obstruction in one patient who developed it and in another patient who underwent alcohol septal ablation prior to TMVR. Valve sizing correlated with actual placed valve size in six out of the eight patients and more than mild paravalvular leak (PVL) was simulated in two of the three patients who had it. Patients who had mismatch between their modeled valve size and post‐procedural imaging were the ones that had anterior leaflet resection which could have altered valve sizing and PVL simulation. 3D printed model of one of the latter patients allowed modification of anterior leaflet to simulate surgical resection and was able to estimate the size and location of the PVL after inserting a valve stent into the physical model.Conclusion3D prototyping in TMVR for severe MAC is feasible for simulating valve sizing, apposition, expansion, PVL, and LVOT obstruction.
Stenting for middle aortic syndrome caused by Takayasu arteritis‐immediate and long‐term outcomes
Authors: Che Wuqiang , Xiong Hongliang , Jiang Xiongjing , Dong Hui , Zou Yubao , Yang Yuejin , Gao Runlin 
Published: January 2018

AbstractObjectiveTo evaluate immediate and long‐term clinical outcomes of stenting for middle aortic syndrome (MAS) caused by Takayasu arteritis (TA).BackgroundStudies of endovascular stenting for the treatment of MAS caused by TA are scare.MethodsData from 48 consecutive TA patients (mean 33.3 ± 12.6 years) with MAS treated by stenting in our institution between January 2010 and July 2016 were collected and retrospectively analyzed. Thirty‐day and long‐term follow‐up clinical outcomes after aorta stenting were assessed.ResultsStenting was successful in all patients. The mean stenosis and peak systolic pressure gradient of aorta lesions were reduced from 81.3 ± 8.0% and 70.7 ± 18.4 mm Hg to 14.7 ± 8.3% and 14.0 ± 5.8 mm Hg immediately after the 54 stents were implanted. One patient developed retroperitoneal hemorrhage and one developed flow‐limiting dissection that involved bilateral renal arteries perioperatively. Both patients recovered without sequela. Compared with baseline, the ankle brachial index (0.92 ± 0.19 vs. 0.75 ± 0.22), mean systolic blood pressure (149.5 ± 19.1 vs. 179.0 ± 28.4 mm Hg) and antihypertensive drugs (1.1 ± 0.7 vs. 3.1 ± 0.9) significantly improved after an average follow‐up of 3.1 years (all P < .001). A total of 5 (10.9%) patients developed in‐stent restenosis, which were resolved by reintervention (restenting in 3 patients and re‐angioplasty alone in 2 patients). No major adverse events occurred during follow up.ConclusionsPercutaneous aortic stenting is highly efficacious and safe in treating patients with MAS caused by TA with good immediate and long‐term clinical outcomes.
Does spotty calcification attenuate the response of nonculprit plaque to statin therapy?: A serial optical coherence tomography study
Authors: Afolabi Abigail , Mustafina Irina , Zhao Linlin , Li Lulu , Sun Rong , Hu Sining , Zhang Shaosong , Jia Haibo , Guilio Guagliumi , Yu Bo 
Published: January 2018

AbstractObjectivesThe aim of this study was to determine if spotty calcification decreases the response of plaque progression to statin therapy.BackgroundPrevious studies showed that the presence of spotty calcification is a marker of vulnerable plaque. However, the relationship between spotty calcification and plaque progression is not clear.MethodsNinety‐six nonculprit lipid‐rich plaques in 69 patients who received serial optical coherence tomography (OCT) imaging were included. Plaques were divided into three groups: spotty calcification (n = 38), calcified (n = 12) and noncalcified (n = 46) plaques. Spotty calcification was identified by the presence of a lesion <4 mm in length with an arc of calcification <90°. Changes in plaque characteristics and fibrous cap thickness (FCT) at 6 and 12 months under statin therapy were analyzed by OCT.ResultsThe increase of FCT was sustained from baseline to 6 and 12 months in three groups: spotty calcification (62.8 ± 20.9, 126.4 ± 84.9, and 169.2 ± 81.6 μm, respectively; P < .001), calcified (59.8 ± 17.0, 93.4 ± 51.4, and 155.2 ± 61.7 μm, respectively; P < .001) and noncalcified (60.0 ± 17.2, 125.5 ± 62.1, and 161.0 ± 80.5 μm, respectively; P < .001). Intensive statin induced a greater change in FCT at 12 months than moderate statin in the spotty calcification group (P = 0.034). The mean lipid arc decreased significantly at 12 months from baseline in the three groups (P = 0.004, P = 0.023, and P < .001, respectively).ConclusionsStatin therapy was effective for plaque stabilization in plaques with and without spotty calcification. Patients with spotty calcification benefitted more from intensive statin than from moderate statin therapy.
Prevalence, Presentation and Treatment of ‘Balloon Undilatable’ Chronic Total Occlusions: Insights from a Multicenter US Registry
Authors: Tajti Peter , Karmpaliotis Dimitri , Alaswad Khaldoon , Toma Catalin , Choi James W. , Jaffer Farouc A. , Doing Anthony H. , Patel Mitul , Mahmud Ehtisham , Uretsky Barry , Karatasakis Aris , Karacsonyi Judit , Danek Barbara A. , Rangan Bavana V. , Banerjee Subhash , Ungi Imre , Brilakis Emmanouil S. 
Published: January 2018

AbstractBackgroundThe prevalence, treatment and outcomes of balloon undilatable chronic total occlusions (CTOs) have received limited study.MethodsWe examined the prevalence, clinical and angiographic characteristics, and procedural outcomes of percutaneous coronary interventions (PCIs) for balloon undilatable CTOs in a contemporary multicenter US registry.ResultsBetween 2012 and 2017 data on balloon undilatable lesions were available for 425 consecutive CTO PCIs in 415 patients in whom guidewire crossing was successful: 52 of 425 CTOs were balloon undilatable (12%). Mean patient age was 65 ± 10 years and most patients were men (84%). Patients with balloon undilatable CTOs were more likely to be diabetic (67 vs. 41%, P < 0.001) and have heart failure (44 vs. 28%, P = 0.027). Balloon undilatable CTOs were longer (40 mm [interquartile range, IQR 20‐50] vs. 30 [IQR 15‐40], P = 0.016), more likely to have moderate/severe calcification (87 vs. 54%, P < 0.001), and had higher J‐CTO score (3.2 ± 1.1 vs. 2.5 ± 1.3, P < 0.001) and PROGRESS‐CTO complications score (3.9 ± 1.7 vs. 3.1 ± 2.0, P < 0.005). They were associated with lower technical and procedural success (92 vs. 98%, P = 0.024; and 88 vs. 96%, P = 0.034, respectively) and higher risk for in‐hospital major adverse events (8 vs. 2%, P = 0.008) due to higher perforation rates. The most frequent treatments for balloon undilatable CTOs were high pressure balloon inflations (64%), rotational atherectomy (31%), laser (21%), and cutting balloons (15%).ConclusionsBalloon undilatable CTOs are common and are associated with lower success and higher complication rates.
Self‐Assembled Magnetic Gold Catalysts from Dual‐Functional Boron Clusters
Authors: Qi Bin , Wu Chenchen , Li Xin , Wang Dan , Sun Liang , Chen Bo , Liu Wenjing , Zhang Haibo , Zhou Xiaohai 
Published: January 2018

AbstractA new class of core–shell magnetic gold nanocomposites is prepared in a raspberry‐like fashion by the controlled supramolecular host–guest assembly of γ‐cyclodextrins (γ‐CDs) and boron clusters. In this work, Cs2[closo‐B12H12], a fundamental boron cluster, can play a dual role in the preparation of highly monodispersed Au nanoparticles and in the immobilization of Au nanoparticles on the γ‐CDs@Fe3O4 surface as an effective anchor. This facile and spontaneous supramolecular strategy allows for the control of the size and composition of the highly stable gold composites. Furthermore, the obtained AuNPs@Fe3O4 composites exhibit an excellent catalytic activity and recyclability for the selective reduction of nitroaromatics to their corresponding aniline compounds, and the fastest reaction can be achieved within 20 s with a high conversion and selectivity at room temperature, which is better than that obtained previously in studies on metal nanoparticle composites as catalysts.
Complete Oxidation of Xylose for Bioelectricity Generation by Reconstructing a Bacterial Xylose Utilization Pathway in vitro
Authors: Wu Ranran , Ma Chunling , Zhang Y.‐H. Percival , Zhu Zhiguang 
Published: January 2018

AbstractA variety of fuels can be utilized to achieve an extraordinarily high energy density in enzymatic fuel cells (EFCs), including glucose, fructose, and sucrose or maltodextrin composed of hexoses. However, xylose, which is the most abundant pentose, has hardly been exploited for bioelectricity generation because of its slow utilization rate and few xylose metabolic pathways in nature. Here, we demonstrate a reconstituted pentose phosphate pathway in vitro composed of 14 enzymes that completely oxidizes xylose. Either ATP or polyphosphate can be used as a phosphate donor in this system. The Faraday efficiency from xylose to electrons by this pathway was as high as 97.0 %, corresponding to the generation of nearly 20 electrons per molecule of xylose. In the presence of 20 mm xylose, an air‐breathing EFC based on the synthetic pathway generated a power density of 0.36 mW cm−2, much higher than that generated by other xylose‐fed bioelectrochemical systems. These results suggest the great potential of the co‐utilization of hexoses and pentoses from renewable abundant biomass for high‐yield bioelectricity generation in the near future.
Feinstaubmessung mit dem Smartphone
Authors: Hauck Bernhard , Schäfer Matthias , Kuhn Jochen , Ulber Roland 
Published: January 2018

ZusammenfassungDer Feinstaubsensor ermöglicht als autonomes System die quantitative Bewertung von Feinstaubquellen im Alltag ohne Gefährdung der Experimentierenden. Selbst starke Emissionsquellen können aus sicherer Entfernung bewertet werden. So lässt sich die Feinstaubproblematik anhand selbst gewonnener Messwerte von der stark befahrenen Straße bis zum ruhigen Waldgebiet ausführlich und anschaulich behandeln.
Study of gas solid turbulent flow in a thermal reactor: Experimental and numerical comparison
Authors: Bellil Ahmed , Benhabib Karim , Coorevits Patrice , Ould‐Dris Aïssa 
Published: January 2018

AbstractDysfunctions observed in thermochemical conversion reactors, like dead zones and short‐ circuits, generally lead to inaccurate pricing of energy resources and air pollution, and originate in the air flow conditions in these aeraulic reactors.[1–3] Therefore, they can be prevented by better control of flows. In this work, we propose to develop a new tool for determining the distribution of residence time of the solid phase, based on the luminescence of particles previously coated with phosphorescent pigments. This optical method, which is non‐intrusive and flexible, has been implemented at a laboratory scale, on an aeraulic test bench.[3]On the other hand, we have developed a numerical model allowing the determination of the distribution of the residence time. This development aims to master the flows at the exit of surrounding walls, which optimizes them and allows their extrapolation to the industrial scale. Our analytical approach is based on modelling by coupling MFN by finite volume types via the Code Saturn, and DEM by discrete elements of the solid behaviour by means of the code SIGRAME. Finally, a confrontation of the RTD of the digital model with the experimental RTD has been conducted.
Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide
Authors: Ruggeri Annalisa , Labopin Myriam , Bacigalupo Andrea , Gülbas Zafer , Koc Yener , Blaise Didier , Bruno Benedetto , Irrera Giuseppe , Tischer Johanna , Diez‐Martin Jose Luiz , Castagna Luca , Ciceri Fabio , Mohty Mohamad , Nagler Arnon 
Published: January 2018

BACKGROUNDIncidence of graft‐versus‐host disease (GVHD) in haploidentical bone marrow (BM) transplants using posttransplantion cyclophosphamide (PT‐Cy) is low, whereas GVHD using mobilized peripheral blood stem cells (PBSC) ranges between 30% and 40%.METHODSTo evaluate the effect of stem cell source in haploidentical transplantation with PT‐Cy, we analyzed 451 patients transplanted for acute myeloid leukemia or acute lymphoblastic leukemia reported to the European Society for Blood and Marrow Transplantation.RESULTSBM was used in 260 patients, and PBSC were used in 191 patients. The median follow‐up was 21 months. Engraftment was lower in BM (92% vs 95%, P < 0.001). BM was associated with a lower incidence of stage II‐IV and stage III‐IV acute GVHD (21% vs 38%, P ≤ .01; and 4% vs 14%, P < .01, respectively). No difference in chronic GVHD, relapse, or nonrelapse mortality were found for PBSC or BM. The 2‐year overall survival (OS) was 55% versus 56% (P = .57) and leukemia‐free survival (LFS) was 49% versus 54% (P = .74) for BM and PBSC, respectively. On multivariate analysis, PBSC were associated with an increased risk of stage II‐IV (hazard ratio [HR], 2.1; P < .001) and stage III‐IV acute GVHD (HR, 3.8; P < .001). For LFS and OS, reduced intensity conditioning was the only factor associated with treatment failure (LFS: HR, 1.40; P = .04) and relapse (HR, 1.62; P = .02).CONCLUSIONIn patients with acute leukemia in first or second remission receiving haploidentical transplantation with PT‐Cy, the use of PBSC increases the risk of acute GVHD, whereas survival outcomes are comparable. Cancer 2018;124:1428‐37. © 2018 American Cancer Society.